PI

SEC source: 0001705407-25-000002 · form4-09242025_040905.xml · nonDerivative · entry 4

Baker Cary · CIK 0001705407 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,479

F1 · kind: In an exempt disposition to the Issuer under Rule 16b-3(e), the Reporting Person remitted shares to the Issuer in connection with the satisfaction of tax withholding obligations arising out of the vesting of restricted stock units, or RSUs.

SEC source: 0001705407-25-000002 · form4-09242025_040905.xml · nonDerivative · entry 3

Baker Cary · CIK 0001705407 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,211

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001705407-25-000002 · form4-09242025_040905.xml · nonDerivative · entry 2

Baker Cary · CIK 0001705407 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,614

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001705407-25-000002 · form4-09242025_040905.xml · nonDerivative · entry 1

Baker Cary · CIK 0001705407 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,135

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001677721-25-000005 · form4-09192025_090952.xml · derivative · entry 5

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,500

Underlying: Common Stock · 7,036 shares

Expires 2028-06-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option became fully vested on June 11, 2022.

SEC source: 0001677721-25-000005 · form4-09192025_090952.xml · derivative · entry 4

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 47,039 shares

Expires 2027-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option became fully vested on July 3, 2021.

SEC source: 0001677721-25-000005 · form4-09192025_090952.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 351,088

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001677721-25-000005 · form4-09192025_090952.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 344,052

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 10

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 297,013

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F11 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $191.61 to $191.77, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 9

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 297,025

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F10 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $190.0001 to $190.545, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 8

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 297,365

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F9 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $188.82 to $189.615, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 7

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 298,215

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F8 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $187.335 to $188.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 6

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 299,288

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F7 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $186.045 to $186.8101, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 5

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 301,109

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $183.30 to $183.88, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 4

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 301,905

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $182.30 to $183.245, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 3

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 303,165

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $181.24 to $182.21, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 305,074

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $180.235 to $180.85, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 305,541

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $179.00 to $179.665, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000003 · form4-09162025_080900.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 306,109

F1 · kind: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's 0% Convertible Senior Notes offering in September 2025, the Reporting Person is permitted to gift up to 30,000 common shares beneficially owned during the lock-up period.

SEC source: 0002003074-25-000016 · primary_doc.xml · nonDerivative · entry 1

SYLEBRA CAPITAL LLC · CIK 0002003074 · See Remarks

Gibson Daniel Patrick · CIK 0001745725 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,829,260

F1 · ownership.nature: Sylebra Capital Limited (Sylebra HK) and Sylebra Capital LLC (Sylebra US) are the investment sub-advisers to Sylebra Capital Partners Master Fund, Ltd. (SCP MF),Sylebra Capital Parc Master Fund (PARC MF), Sylebra Capital Menlo Master Fund (MENLO MF), and other advisory clients. Sylebra Capital Management (Sylebra Cayman) is the investment manager and parent of Sylebra HK. Sylebra Cayman owns 100% of the shares of Sylebra HK, and Daniel Patrick Gibson (Gibson) owns 100% of Class A shares of Sylebra Cayman and 100% of the share capital of Sylebra US. Gibson is a founder and Chief Investment Officer of Sylebra Cayman. In such capacities, Sylebra HK,Sylebra US, Sylebra Cayman and Gibson may be deemed to share voting and dispositive power over the shares of common stock of the Issuer held by SCP MF,PARC MF,MENLOMF, and other advisory clients.

F2 · ownership.nature: These securities are held by SCP MF, PARC MF, MENLO MF, and/or other advisory clients. Gibson is a member of the board of directors of the Issuer. Sylebra HK, Sylebra US, Sylebra Cayman and Gibson disclaim beneficial ownership of these securities, and this report shall not be deemed an admission that Sylebra HK, Sylebra US,Sylebra Cayman and Gibson are the beneficial owners of such securities, except to the extent of their pecuniary interest, if any, therein.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 12

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 336,109

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 11

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 336,276

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F11 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $197.78 to $198.05, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 10

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 336,579

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F10 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $196.76 to $197.75, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 9

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 337,369

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F9 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $195.75 to $196.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 8

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 337,618

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F8 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $194.71 to $195.6975, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 7

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 338,738

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F7 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $193.635 to $194.62, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 6

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 340,070

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $192.455 to $193.28, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 5

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 340,580

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $191.25 to $191.37, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 4

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 340,779

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $190.19 to $190.83, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 3

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 341,109

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 341,209

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $192.17 to $193.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 344,216

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $191.17 to $192.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023612 · form4-09042025_120914.xml · nonDerivative · entry 6

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 346,109

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $190.0000 to $190.4050, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023612 · form4-09042025_120914.xml · nonDerivative · entry 5

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 348,666

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $188.9201 to $189.8300, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023612 · form4-09042025_120914.xml · nonDerivative · entry 4

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 350,104

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $187.8650 to $188.4050, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023612 · form4-09042025_120914.xml · nonDerivative · entry 3

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 351,029

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

SEC source: 0001415889-25-023612 · form4-09042025_120914.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 351,109

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $181.185 to $181.54, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023612 · form4-09042025_120914.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 351,592

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $180.00 to $180.82, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023326 · form4-08292025_110828.xml · nonDerivative · entry 9

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 356,109

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

SEC source: 0001415889-25-023326 · form4-08292025_110828.xml · nonDerivative · entry 8

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 356,309

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F9 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $189.10 to $189.74, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023326 · form4-08292025_110828.xml · nonDerivative · entry 7

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 359,109

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F8 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $188.00.00 to $188.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein

SEC source: 0001415889-25-023326 · form4-08292025_110828.xml · nonDerivative · entry 6

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 361,109

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F7 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $190.75 to $190.93, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023326 · form4-08292025_110828.xml · nonDerivative · entry 5

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 361,179

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $189.70 to $190.675, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023326 · form4-08292025_110828.xml · nonDerivative · entry 4

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 361,504

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $188.585 to $189.335, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023326 · form4-08292025_110828.xml · nonDerivative · entry 3

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 362,464

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $187.5801 to $188.57 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023326 · form4-08292025_110828.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 364,213

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $186.43 to $187.305, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023326 · form4-08292025_110828.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 364,997

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $185.34.00 to $186.32, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-022640 · form4-08212025_090832.xml · derivative · entry 1

Baker Cary · CIK 0001705407 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,958

Underlying: Common Stock · 6,958 shares

Expires not disclosed

F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Impinj common stock.

F2 · derivative.exercise_date: One-fourth of the shares subject to the grant shall vest on August 20, 2026, and 1/16th of the shares subject to the grant shall vest each quarter thereafter, subject to the reporting person's continued service to the Issuer through such date.

F2 · derivative.expiration_date: One-fourth of the shares subject to the grant shall vest on August 20, 2026, and 1/16th of the shares subject to the grant shall vest each quarter thereafter, subject to the reporting person's continued service to the Issuer through such date.

SEC source: 0001415889-25-022639 · form4-08212025_090833.xml · derivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,015

Underlying: Common Stock · 15,015 shares

Expires not disclosed

F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Impinj common stock.

F2 · derivative.exercise_date: One-fourth of the shares subject to the grant shall vest on August 20, 2026, and 1/16th of the shares subject to the grant shall vest each quarter thereafter, subject to the reporting person's continued service to the Issuer through such date.

F2 · derivative.expiration_date: One-fourth of the shares subject to the grant shall vest on August 20, 2026, and 1/16th of the shares subject to the grant shall vest each quarter thereafter, subject to the reporting person's continued service to the Issuer through such date.

SEC source: 0001415889-25-018135 · form4-06242025_110643.xml · derivative · entry 7

Baker Cary · CIK 0001705407 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,563

Underlying: Common Stock · 596 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Impinj common stock.

F5 · derivative.exercise_date: On March 23, 2024, the reporting person was granted 9,545 RSUs. One-sixteenth of these vested on June 23, 2025.

F5 · derivative.expiration_date: On March 23, 2024, the reporting person was granted 9,545 RSUs. One-sixteenth of these vested on June 23, 2025.